In terms of overcoming bacterial biofılms, phages alone or combined with chlorine outperform several other conventional treatments, according to environmental engineer Zhiqiang Hu and graduate student Yanyan Zhang at the University of Missouri, Columbia. Thus, they say, phages might be useful for treating stubborn biofılms that form and are diffıcult to remove in water treatment plants and in other industrial or clinical settings. More specifıcally, bacteriophages recovered from municipal wastewater kill about twice as many Pseudomonas aeruginosa bacteria in established biofılms as does chlorine, and the two treatments combined destroy nearly all the bacteria in sample biofılms, they report in the August 2012 Biotechnology and Bioengineering [doi:10.1002/ bit.24630] .
After collecting samples of untreated wastewater from a local sewage treatment facility, Zhang and Hu then selected phages that specifıcally target P. aeruginosa biofılms. They sought bacteriophages that can stop biofılms from forming as well as kill P. aeruginosa in biofılms that are already formed. In some of their tests, the researchers simulated what occurs on fıl-ters that are used in water purifıcation plants.
For example, in a continuous-flow system that simulates conditions at water treatment facilities, chlorine alone removed 40% of biofılms, and bacteriophages removed 89% of biofılms. Initial treatment with bacteriophages followed by chlorine knocked out 97% of biofılms within fıve days. In other lab tests with samples in microwells, high concentrations of chlorine prevent biofılms from forming about as well as did treating those microwells with purifıed bacteriophages. When both agents were acting together, they worked better than when used apart in keeping biofılms from forming. However, the bacteriophage outperform high concentrations of chlorine in treating existing biofılms, although adding chlorine plus bacteriophages outperforms the latter when it is used alone, according to Zhang and Hu.
Bacteriophages excel because they target specifıc bacteria in biofılms, not only working along their surfaces but also lysing bacterial cells well below those surfaces. Chlorine kills only those bacteria on the outer layers of biofılms, according to Zhang and Hu. Examining samples via transmission electron microscopy also indicates that bacteriophages are more effective at penetrating biofılms and then lysing cells to produce debris than is chlorine. Here again, combining these two treatments proves more damaging than either one of them used alone.
Biofılms often clog fılters at water treatment plants, requiring plant operators to back flush those fılters, an expensive and time-consuming process. A bacteriophage-chlorine treatment offers a possible alternative. "The goal is to select bacteriophage cocktails that remove pathogenic bacteria with minimal impact on benefıcial bacteria," says Hu.
Drinking water supplies typically are treated with chemicals and biocides. However, after many decades, some of these microorganisms are resistant to these methods, particularly those that form biofılms, and "there's a clear need for novel treatments," says Claudia Gunsch, an environmental engineer at Duke University in Durham, N.C. Targeting microbes in biofılms with specifıc bacteriophages "could ultimately lead to greener disinfection technologies," she says. This potential use raises questions about the safety of residual bacteriophages for consumers.
Carol Potera is a freelance writer in Great Falls, Mont.
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Triple Adjuvant Might Lead to Single-Dose Pertussis Vaccine Shannon Weiman
An experimental pertussis vaccine combining three adjuvants with a single antigen is being developed to be given in a single dose-offering lifelong protection and lower cost than the current vaccine, according to Volker Gerdts, Associate Director of Research at VIDO-InterVac at the University of Saskatchewan in Saskatoon, Saskatchewan, Canada. This same approach is applicable to vaccines that protect against other bacterial or viral pathogens and, potentially, parasites such as the one that causes malaria, he says. Gerdts spoke during the symposium "Host Defense (Antimicrobial) Peptides: Major Players in Health and Novel Therapeutics," during the 2012 ICAAC, held in San Francisco last September.
Gerdts and his collaborators set high goals for their updated pertussis vaccine to meet. It should be affordable, easy and safe to administer in resource-limited settings, offer lifetime immunity following a single dose, and be effective in protecting newborn children, in whom maternal antibodies tend to block vaccine effıcacy. Meanwhile, the widely used pertussis vaccine, which typically is administered fıve times to U.S. children before they begin school, is under scrutiny after recent outbreaks of the disease (Microbe, October 2012, p. 455) .
Key to meeting at least some of those goals is a novel adjuvant containing three ingredients-a synthetic innate defense regulatory peptide, a Toll-like receptor (TLR) ligand, and polyphosphazene, a nitrogen-and phosphorous-containing polymer with organic side chains. These three components activate potent and lasting immune responses, depending in part on the polymer encapsulating the antigen within a microparticle, according to Gerdts. Its surface is coated with the two other components, which recruit dendritic and macrophage cells of the host immune system that engulf the particles, process the antigens inside, and activate protective host responses, he says. "Particulate delivery increases vaccine stability and uptake of the antigen to the MHC class I and class II compartments, resulting in induction of both cell-mediated and humoral immune responses."
When tested in animals, the singledose pertussis vaccine is extremely potent. It confers lifetime protection with a single dose in mice and piglets, even in the presence of maternal antibodies. "Regardless of level of maternal antibodies, we see complete protection in all of our animals," Gerdts says. The three-component adjuvant may preserve antigens within the microparticles, insulating against maternal antibodies interference, he speculates.
This version of the pertussis vaccine, if safe and effective, would be well suited for children in developing nations because of single dosing and its low cost, mere cents per dose, Gerdts says. It also can be delivered via inhaler, which is easier, potentially safer, less invasive, and elicits a good mucosal immune response in the lung, the main site of pertussis infections.
Other vaccines are being fıt within this adjuvant platform, according to Gerdts. For example, a candidate vaccine to protect against respiratory syncytial virus is slated to begin clinical trials in 2014, he says. The adjuvant also is being eyed for use in veterinary medicine to protect livestock and poultry against a multitude of diseases.
Shannon Weiman is a freelance writer in San
Francisco, Calif.
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Report from Global Academies Renews Call for Scientific Integrity
"All researchers have an obligation to act in accord with the values and principles of research integrity," says Indira Nath, an emeritus professor at the National Institute of Pathology in New Delhi, India. Nath cochaired a committee of IAP, the global network of science academies in Trieste, Italy, and the InterAcademy Council in Amsterdam, the Netherlands, whose members issued a report last October that promotes research integrity worldwide. Although national practices vary, "global standards of behavior reflecting the universal values of research are not only possible, but necessary," adds cochair Ernst-Ludwig Winnacker, the secretary general of the Human Frontier Science Program in Strasbourg, France. The report identifies values and principles for scientists to incorporate into every part of the research process, from developing a research plan to reporting results and communicating with policymakers and the public. The report, "Responsible Conduct in the Global Research Enterprise: A Policy Report," can be found on the IAP and IAC websites at www.interacademies.net and www.interacademycouncil.net. By adding a genetic "barcode" to the genome of relatively harmless Bacillus thuringiensis subsp kurstaki (Btk), this bacterial species can be used much more effectively to simulate how Bacillus anthracis-a far more dangerous pathogen, whose spores might be used again by terrorists-disperses in various environments, according to Henry S. Gibbons of the Edgewood Chemical Biological Center at Aberdeen Proving Ground in Aberdeen, Md., and his collaborators. Without that special coding, it is virtually impossible to distinguish Btk spores that are deliberately released in simulatory experiments from those that are naturally occurring, they point out. Their fındings appeared online September 21, 2012 in Applied and Environmental .
"We were most interested in studying the question of biological agent reaerosolization-the possibility that, once an agent is released and settles onto a surface, perturbation of that surface might resuspend the material, posing further risks to personnel in the area," Gibbons says. However, the traditional agent used to simulate anthrax spores, Bacillus atrophaeus var. globigii, fails to share several key physical properties with B. anthracis. Meanwhile, 90 years of using Btk as a pesticide, along with its being a better match physically for B. anthracis, make Btk a better surrogate, he says. However, its wide distribution and persistence in outdoor and indoor settings could confound efforts to interpret spore dispersal experiments.
Thus, Gibbons and his collaborators installed a barcode, marking Btk in a nongene coding region of its genome, as a surefıre way to distinguish the experimental from the naturally distributed version of this microorganism.
Not fully satisfıed, the team researchers already are developing another set of marker modules, which Gibbons says will be more compatible with the TaqMan assay that is used to detect Btk in various environments. "We're hoping to have strains containing those in early 2013," he says.
"Issues about whether spores, once deposited, can reaerosolize from contaminated surfaces, and how long the spores stay viable in different environments, have not been answered conclusively," says Paul Jackson of Lawrence Livermore National Laboratory in Livermore, Calif. Studies using such agents might help answer these questions, which Jackson says "are very signifıcant to those who might need to respond to a release." It cost $23 million to decontaminate the Hart Senate Offıce Building following its contamination from anthrax spores released from letters sent to offıcials there in 2001.
"The wider use of this tool could allow governmental agencies, including the Department of Homeland Security and the armed forces, to establish plans for emergency responses that are directly informed by the dispersion data derived from the use of the described methodology," says Ian Glomsky of the University of Virginia, Charlottesville. "It is really neat to see basic science in the fıeld. As an anthrax researcher, it rarely crosses my mind that there is a whole world of relatively untested conditions that in many ways defıne whether a pathogen causes disease more so than the genomes and host immunology [we] wet laboratory researchers often focus on; things like wind direction, residence time of particles in the air, reaerosolization, and persistence of the pathogen on surfaces." directions. Curiously, although these projects may be moving forward under the banner of rational development, the fındings can harbor mechanistic surprises, according to several scientists who participated in the symposium "New Treatments for Mycobacterium tuberculosis Infections," convened as part of the 2012 ICAAC, held in San Francisco last September.
M. tuberculosis, a pathogen with a waxy cell wall and lethargic growth habits, has a way of "confounding" rational searches for new drugs with which to treat it, according to Carol Nacy of Sequella, Inc., in Rockville, Md., an organizer of the ICAAC symposium. Hence, she and her colleagues favor testing promising drug candidates in vivo very early during their development. Part of the rationale behind such early testing of candidate drugs in animals is that "it's easier to make an active drug better than to work with compounds that hit particular targets," she says.
With that precept in mind, Nacy and her collaborators reexamined ethambutol (EMB), a drug that is already licensed for treating tuberculosis, "to look at making it better," she says. Their ensuing medicinal chemistry-based approach entailed making systematic changes in its linkages and side groups, leading to a set of some 25,000 compounds built on 8 new scaffolds.
"We ended up with dipiperidines as the most promising," she continues, referring to a particular set of EMB derivatives. "All are cell-wall active as is EMB, the antibiotic with which we began." Three dipiperdine compounds emerged as worth pursuing still further, including one designated SQ609 that also proves consistently more active against clinical isolates of the pathogen than against lab strains. Amid improvements in activity and other traits, it continues to disrupt the M. tuberculosis cell wall, although its specifıc target there is unknown. On top of its antimicrobial properties, SQ609 has anti-inflammatory activity, Nacy says.
Active against the pathogen when used alone, SQ609 becomes synergistic when combined with very different anti-M. tuberculosis agents, but also when used with the parent compound EMB. Another drug in this same series, designated SQ109, also synergizes with SQ609 but not with EMB. "All have different mechanisms and different physiochemical characteristics," Nacy says. Yet, both SQ109 and SQ609 derived from EMB via "rational" medicinal chemistry-based steps. Go fıgure.
Another and wholly separate set of drug candidates, including one that has promising activity against M. tuberculosis, also offers some mechanistic surprises, according to Annelise Barron of Stanford University in Stanford, Calif., another speaker at this ICAAC symposium. Her interests focus on chemically modifıed antimicrobial peptides that she calls peptoids, which in general are altered to be less polar but more flexible than their parent peptide compounds. Reducing the net charge makes the peptoids better suited for penetrating the waxy membranes that surround M. tuberculosis cells, she says.
Antimicrobial peptides are widely believed to act by disrupting membranes. The big surprise here is that these peptoids, including one designated LL-37 that is particularly active against M. tuberculosis, appear to destroy target cells by inducing their ribosomes to aggregate, according to Barron. "There is not that much leakage from the microbial cell after treatment with peptoids," she says. "What correlated with their antimicrobial activity is ribosomal aggregation. And we are quite confıdent that LL-37 works this way."
Jeffrey L. Fox is the Microbe Current Topics and Features Editor.
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Analysis Shows Bacterial Transcription Complex Binding, Organizing DNA Marcia Stone
The fırst high-resolution, three-dimensional structure of the molecular complex with which cells read and transcribe genetic information from DNA into RNA reveals how the complex recognizes, binds, unwinds, and organizes-or "preorganizes," as Ebright likes to say-DNA for various reactions, according to Richard H. Ebright, Eddy Arnold, and their collaborators at Rutgers Uni-
MINITOPIC
Deadly Meningitis Outbreak Leads to Recall of Medicines
A multistate outbreak of fungal meningitis led to at least 32 deaths among 438 cases in 19 states as of early November, according to officials from the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. The infections are linked to contaminated lots of injectable steroids (methylprednisolone acetate) that were produced, distributed, and now recalled by the New England Compounding Center (NECC) in Framingham, Mass. Although the patient identified as the index case of this outbreak was infected with Aspergillus fumigatus, many more of the patients are infected with Exserohilum rostratum, which is less frequently a pathogen of humans and known better as a mold associated with soils and plants, particularly grasses. As part of a wider response to the initial outbreak from contaminated medicinal products, Ameridose LLC of Westborough, Mass.-a company that shares management with NECC-similarly withdrew all its products from the market as of 31 October 2012, according to officials of the Food and Drug Administration (FDA). versity in Piscataway, N.J. Details appear in Science (338:1076 -1080).
This newly determined structure of the transcription initiation complex looks at RNA polymerase (RNAP) and the transcription initiation factor sigma from the bacterium Thermus thermophilus. "Determining the structure of a functional transcription initiation complex has been the goal of scientists for more than three decades," Arnold says. The structure helps determine interactions between RNAP and sigma with the DNA promoter segment. When transcription begins, RNAP and sigma unwind about13 bp of promoter DNA to form a singlestranded "transcription bubble," yielding a RNAP-sigma-promoter open complex, called simply the RNAP-promoter open complex (RPo).
"RPo is the critical catalytically competent intermediate in transcription initiation and modulation of its formation, stability, and activity by repressors, and activators are an important means of regulating gene expression," explains Ebright.
Three specifıc DNA sequence elements to which RNAP and sigma bind within the promoter include a newly recognized "core recognition element" along with previously described "-10" and "discriminator" elements. RNAP binds the core recognition element, whereas sigma binds both the -10 and discriminatory elements.
"A striking feature of the interactions between the transcription complex and these three elements is that RNAP and sigma unstack the DNA bases, flip them 180 degrees, and insert them into pockets formed by RNAP and sigma residues," says research team member Yu Zhang. "The importance of the interactions with unstacked, flipped bases is that they provide a means to drive promoter unwinding," adds Ebright. Additionally, another part of the sigma, which these researchers term the "sigma fın-ger," interacts with the template strand of the transcription bubble, organizing it for subsequent reactions.
Not only does visualization of this structure provide a new understanding of bacterial transcription initiation and regulation, it offers a starting point for the development of new antimicrobial agents, say these researchers.
"Rifampicin, the prototype RNA polymerase inhibitor, has been successfully used for years and remains a front-line agent for the treatment of multidrug-resistant tuberculosis. However, it requires dosing for six months, and resistance is common," comments Julian Davies at the University of British Columbia in Vancouver, Canada. "This structure will guide the mechanism-based design of novel inhibitors of bacterial transcription." "The polymerases, more than anything else except the ribosome, show us how 4 billion years can turn elaborate function into elegant structure," says Michael Yarus at the University of Colorado in Boulder. August 26, 2012 in Nature Nanotechnology (7:602-608) .
Marcia Stone is a science writer based in
The NEMS device is a highly specialized, miniature mass spectrometer (MS) that measures molecular weights of molecules such as proteins or RNA and DNA. Because of advances in circuitry design, software, and detection sensitivity, this device can give instant readouts. Unlike even newer tabletop MS instruments, this new NEMS-MS combines its components into an exceedingly small package that is only a few millionths of a meter across. A key component, a vibrating resonator called a "bridge," responds to molecular adsorption events that reflect the masses of molecules being analyzed.
The device can measure the mass of individual proteins that are extracted from cells as part of the analytic process, according to lead author Hanay. This system "can detect large molecules effıciently [unlike] conventional MS, which faces diffıculties in measuring molecules larger than a few megadaltons," he says. Its properties put it "in a unique position for the studies of large biomolecules." Moreover, it can be used to "weigh and identify an entire virus by itself." peutics," during the 2012 ICAAC, held in San Francisco last September.
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Defensins are cysteine-containing peptides that are components of the innate immune system in both vertebrates and invertebrates. In humans, they are produced by skin, mucosal surfaces, and neutrophils as a fırst line of defense against microbes. As therapeutic products, however, they can be cytotoxic for mammalian cells. To counteract such effects, PolyMedix followed medicinal chemistry principles, building nonpeptide scaffolds with rigid cores and modifying side chains to improve microbial selectivity.
These efforts yield both narrow-and broad-spectrum antimicrobial agents that are bactericidal against both grampositive and gram-negative bacteria, according to Scott. "Preclinical studies show that our defensin-mimetic compounds have activity against a number of biowarfare pathogens, including those that cause anthrax, plague, tularemia, listeriosis, and others," he says. These agents are also effective against clinically important conventional pathogens, many of which are drug resistant, such as methicillin-resistant Staphylococcus aureus (MRSA).
The most advanced candidate drug, brilacidin, is under development as a systemic antibiotic and has successfully completed a phase II clinical trial in acute bacterial skin and skin structure infections caused by staphylococci. It is also being developed for topical use as a rinse for oral mucositis, a debilitating side effect of chemotherapy for which there is no specifıc treatment.
Other compounds in this set have potent antifungal activity, Scott says. For instance, PMX1502 is fungicidal against Candida albicans in animal infection models, unlike fluconazole, which is fungistatic. When treated with PMX1502, mice with systemic fungal infections show 100% survival compared to 40% when treated with fluconazole. Moreover, PMX1502 and another defensin mimetic compound, PMX519, are signifıcantly more effective than the polyene antifungal drug Nystatin in treating oral candidiasis in mice.
Yet others among these nonpeptide candidates target tuberculosis and malaria, Scott says. The PolyMedix antimalaria candidate, for example, selectively disrupts the digestive vacuole of the parasite, improving mouse survival substantially.
Each of these selective antimicrobial candidate products is expected to be well tolerated in humans, based on fındings from phase II clinical testing of brilacidin. Remarkably, microbes do not develop resistance to these agents when tested in serial passage assays, according to Scott. The compounds target and disrupt the microbial cell membranes, a process that seems less likely to lead to resistance mutations than targeting specifıc microbial proteins. Moreover, unlike conventional antibiotics, microbes have not developed resistance to defensins themselves despite their presence in innate immunity for hundreds of millions of years.
